Form 4: Adverum Biotechnologies Director Patrick Machado Granted Stock Options

Adverum Biotechnologies, Inc. Director Patrick Machado was granted stock options to purchase 13,590 shares of common stock at an exercise price of $2.32 per share, vesting in 2026.

Summary

• Patrick Machado, a Director of Adverum Biotechnologies, Inc. (ADVM), was granted stock options on June 17, 2025.
• The grant includes two tranches of stock options: 10,450 shares and 3,140 shares, totaling 13,590 shares.
• Both tranches have an exercise price of $2.32 per share.
• The options will vest and become exercisable on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.
• Vesting is contingent upon Mr. Machado's continued service with the Issuer on the vesting date.
• Accelerated vesting will occur upon a change of control.
• The expiration date for both sets of options is June 16, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (stock option grant) which is a standard compensation practice. It is generally neutral to slightly positive as it aligns director interests with shareholders, but does not contain significant new financial performance data.

Positives

• The grant of stock options aligns the interests of Director Patrick Machado with those of the shareholders, incentivizing long-term value creation.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Risks

• The vesting of the stock options is subject to the Reporting Person's continued service with Adverum Biotechnologies, Inc. on the vesting date.
• The value of the options is dependent on the future stock price of Adverum Biotechnologies, Inc. exceeding the exercise price of $2.32.

Future Outlook

The stock option grants are designed to incentivize the director's continued service and align their interests with the company's long-term performance, with vesting scheduled for 2026.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology industry and publicly traded companies to attract, retain, and incentivize board members by aligning their financial interests with shareholder value.

Related Party Transactions

• The document details the grant of stock options to Patrick Machado, a Director of Adverum Biotechnologies, Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's long-term interests with shareholder value creation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options are expected to vest on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Patrick Machado